
-
Tonix Pharmaceuticals NasdaqCM:TNXP Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.
Location: 26 Main Street, Chatham, NJ, 07928, United States | Website: https://www.tonixpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
32.83M
Cash
98.78M
Avg Qtr Burn
-15.23M
Short % of Float
15.17%
Insider Ownership
0.00%
Institutional Own.
4.22%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TNX-102 SL (Tonmya™) Details Fibromyalgia | PDUFA Approval decision | |
TNX-1300 Details Cocaine overdose / intoxication | Phase 2 Data readout | |
TNX-1900 Details Social Anxiety Disorder | Phase 2 Data readout | |
TNX-1900 Details Obesity | Phase 2 Data readout | |
TNX-1900 Details Psychiatric disorder, Binge eating disorder | Phase 2 Data readout | |
TNX-1900 Details Bone disorder, Bone health, Autism spectrum disorders | Phase 2 Data readout | |
TNX-102 SL Details Sleeping disorder, Post-traumatic stress disorder | Phase 2 Update | |
TNX-102 SL Details COVID-19 | Phase 2 Update | |
TNX-2900 Details Prader-Willi syndrome | Phase 2 Initiation | |
TNX-102 SL Details Post-traumatic stress disorder | Phase 2 Initiation | |
TNX-1500 Details Kidney transplantation, Graft-versus-host disease , Hematopoietic cell transplantation | Phase 2 Initiation | |
TNX-801 (recombinant horsepox virus Details Monkeypox, Smallpox | IND Submission | |
TNX-102 SL Details Alcohol dependence | Failed Discontinued | |
TNX-102 SL Details Agitation, Alzheimer's disease | Failed Discontinued | |
TNX-1900 Details Migraines | Failed Discontinued | |
TNX-601 Details Major depressive disorder | Failed Discontinued |